Human Papillomavirus Testing in the Last Cervical Screening Round at Age 60-64 Years.
Journal
Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
15
01
2021
accepted:
06
05
2021
pubmed:
6
8
2021
medline:
5
10
2021
entrez:
5
8
2021
Statut:
ppublish
Résumé
To compare the real-life screening outcomes after cytology was replaced by human papillomavirus (HPV) testing for women aged 60-64 years. Using the Danish national pathology register, we compared screening outcomes during two consecutive calendar periods, one where women were screened with cytology and one where most women were screened with HPV testing. Our primary outcomes were the proportions of women with positive test results, high-grade cervical intraepithelial neoplasia (CIN 2 or worse), and cervical cancer. Women screened during the HPV testing period were more likely to have a positive screening test result than were women screened during the cytology period (relative proportion 2.80, 95% CI 2.65-2.96). The detection of CIN 2 or worse was also increased (relative proportion 1.54, 95% CI 1.31-1.80), whereas there was no increase in screen-detected cervical cancer diagnoses (relative proportion 1.27, 95% CI 0.76-2.12). Within the first 4 years after a negative screening test result, including 168,477 woman-years at risk after a negative screen result in the HPV period and 451,421 woman-years after a negative screen result in the cytology period, the risk of a cervical cancer diagnosis was approximately 4 per 100,000 woman-years and was similar for both screening tests (relative risk 0.99, 95% CI 0.41-2.35). Human papillomavirus testing led to more positive screening test results and diagnoses of high-grade CIN lesions. Few women were diagnosed with cervical cancer after a negative screening test result.
Identifiants
pubmed: 34352844
doi: 10.1097/AOG.0000000000004522
pii: 00006250-202109000-00011
pmc: PMC8366760
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
389-397Subventions
Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32. doi: 10.1016/S0140-6736(13)62218-7
doi: 10.1016/S0140-6736(13)62218-7
Aitken CA, van Agt HME, Siebers AG, van Kemenade FJ, Niesters HGM, Melchers WJG, et al. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study. BMC Med 2019;17:228. doi: 10.1186/s12916-019-1460-0
doi: 10.1186/s12916-019-1460-0
Ronco G, Giorgi Rossi P, Giubilato P, Del Mistro A, Zappa M, Carozzi F. A first survey of HPV-based screening in routine cervical cancer screening in Italy. Epidemiol Prev 2015;39:77–83.
Sundhedsstyrelsen. Screening for livmoderhalskræft—anbefalinger. Accessed November 18, 2020. https://www.sst.dk/∼/media/B1211EAFEDFB47C5822E883205F99B79.ashx
Danckert B, Ferlay J, Engholm G, Hansen HL, Johannesen TB, Khan S, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries. Version 8.2. (26.3.2019). Association of the Nordic Cancer Registries. Danish Cancer Society. Accessed November 18, 2020. http://www.ancr.nu/
Lynge E, Clausen LB, Guignard R, Poll P. What happens when organization of cervical cancer screening is delayed or stopped? J Med Screen 2006;13:41–6. doi: 10.1258/096914106776179773
doi: 10.1258/096914106776179773
Rebolj M, Bonde J, Ejegod D, Preisler S, Rygaard C, Lynge E. A daunting challenge: human papillomavirus assays and cytology in primary cervical screening of women below age 30 years. Eur J Cancer 2015;51:1456–66. doi: 10.1016/j.ejca.2015.04.012
doi: 10.1016/j.ejca.2015.04.012
Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E. Human papillomavirus assays and cytology in primary cervical screening of women aged 30 Years and above. PLoS One 2016;11:e0147326. doi: 10.1371/journal.pone.0147326
doi: 10.1371/journal.pone.0147326
Gravitt PE, Landy R, Schiffman M. How confident can we be in the current guidelines for exiting cervical screening? Prev Med 2018;114:188–92. doi: 10.1016/j.ypmed.2018.07.005
doi: 10.1016/j.ypmed.2018.07.005
Tranberg M, Larsen MB, Mikkelsen EM, Svanholm H, Andersen B. Impact of opportunistic testing in a systematic cervical cancer screening program: a nationwide registry study. BMC Public Health 2015;15:681. doi: 10.1186/s12889-015-2039-0
doi: 10.1186/s12889-015-2039-0
Styregruppen for DKLS. Årsrapport DKLS 2019: dansk Kvalitetsdatabase for Livmoderhalskræftscreening. Accessed November 18, 2020. https://www.sundhed.dk/content/cms/82/4682_dkls_aarsrapport_2019_off_version.pdf
Lam JU, Lynge E, Njor SH, Rebolj M. Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark. Acta Oncol 2015;54:1136–43. doi: 10.3109/0284186X.2015.1016625
doi: 10.3109/0284186X.2015.1016625
Bjerregaard B, Larsen OB. The Danish pathology register. Scand J Public Health 2011;39:72–4. doi: 10.1177/1403494810393563
doi: 10.1177/1403494810393563
Rebolj M, Njor S, Lynge E, Preisler S, Ejegod D, Rygaard C, et al. Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening. Cytopathology 2017;28:419–28. doi: 10.1111/cyt.12451
doi: 10.1111/cyt.12451
Rebolj M, Rask J, van Ballegooijen M, Kirschner B, Rozemeijer K, Bonde J, et al. Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in Denmark. Br J Cancer 2015;113:1259–74. doi: 10.1038/bjc.2015.339
doi: 10.1038/bjc.2015.339
Kristensson JH, Sander BB, von Euler-Chelpin M, Lynge E. Predictors of non-participation in cervical screening in Denmark. Cancer Epidemiol 2014;38:174–80. doi: 10.1016/j.canep.2013.12.007
doi: 10.1016/j.canep.2013.12.007
Styregruppen for DKLS. Årsrapport DKLS 2010: dansk Kvalitetsdatabase for Livmoderhalskræftscreening. Accessed November 18, 2020. https://www.sundhed.dk/content/cms/80/1880_aarsrapport-2010-livmoderhalskraeftscreening.pdf
Styregruppen for DKLS. Årsrapport DKLS 2016: dansk Kvalitetsdatabase for Livmoderhalskræftscreening. Accessed November 18, 2020. https://www.sundhed.dk/content/cms/82/4682_dkls_%C3%A5rsrapport2016_offentligversion.pdf
Vaccarella S, Franceschi S, Engholm G, Lönnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 2014;111:965–9. doi: 10.1038/bjc.2014.362
doi: 10.1038/bjc.2014.362
Castañón A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med 2014;11:e1001585. doi: 10.1371/journal.pmed.1001585
doi: 10.1371/journal.pmed.1001585
Andersen B, Christensen BS, Christensen J, Ejersbo D, Heje HN, Jochumsen KM, et al. HPV-prevalence in elderly women in Denmark. Gynecol Oncol 2019;154:118–23. doi: 10.1016/j.ygyno.2019.04.680
doi: 10.1016/j.ygyno.2019.04.680
Dansk Kvalitetsdatabase for Livmoderhalskræftscreenings styregruppe og RKKPs Videnscenter. Resultater fra Engangstilbuddet: Livmoderhalskræftscreening blandt danske kvinder født før 1948: 2. delrapport. Accessed November 18, 2020. https://www.sundhed.dk/content/cms/82/4682_2_del_engangstilbuddet_off_version.pdf
Elit L. Role of cervical screening in older women. Maturitas 2014;79:413–20. doi: 10.1016/j.maturitas.2014.09.012
doi: 10.1016/j.maturitas.2014.09.012
Petersen LK. National klininsk retningslinje for celleforandringer på livmoderhalsen. Udredning, behandling og opfølgning med fokus på kvinder over 60 år. Accessed November 18, 2020. https://www.sst.dk/-/media/Opgaver/Patientforl%C3%B8b-og-kvalitet/NKR/Puljefinansierede-NKR/pdf-version-af-published_guideline_2633.ashx?la=da&hash=0809DD9A773B341B3D08AE73C9361E2AB84029E8
Barken SS, Rebolj M, Andersen ES, Lynge E. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 2012;130:2438–44. doi: 10.1002/ijc.26248
doi: 10.1002/ijc.26248
Danmarks Statistik. HISB9: average life expectancy. Life table (5 years table) by life table, sex, age and time. Accessed November 18, 2020. https://www.statistikbanken.dk/HISB9
Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013;178:1161–9. doi: 10.1093/aje/kwt077
doi: 10.1093/aje/kwt077
van den Akker-van Marie ME, van Ballegooijen M, Rozendaal L, Meijer CJ, Habbema JD. Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer 2003;89:1830–3. doi: 10.1038/sj.bjc.6601355
doi: 10.1038/sj.bjc.6601355